|
|
| |
 |
Recombinant Proteins in Cancer |
 |
|
|
|
|
Recombinant Proteins in Cancer
|
|
Perspective
- Pioneer in design and production of recombinant proteins in the field of cancer in Iran.
Purpose
- Meeting recombinant protein demands of the medical field with the help of specialists for developing a better and healthier future.
Aims
- Establishing required foundations and laboratories in the field of biotechnology and optimization and transfer of technology.
- Training specialists in the field of biotechnology.
- Design and development of recombinant proteins, particularly recombinant antibodies for application in research, diagnosis and cancer treatment.
- Conducting student research tesis and industrial projects in laboratorial scale, in the field of antibody production.
- Expanding antibody production from laboratorial to semi-industrial or furder scales in the form of knowledge based companies and collaboration with other institutions and companies.
- Study and design of research projects in the field of developing production cycles of recombinant proteins in short and long term phases.
- Determination of research priorities concerning mAbs in the country and solving them.
|
|
|
|
| View: 2419 Time(s) | Print: 471 Time(s) | Email: 0 Time(s) | 0 Comment(s) |
|
|
| |
|
|
|
Members |
|
|
| | Post date: 2017/11/12 | |
|
Members
| Name |
Field of study |
Position |
| Dr. Leila Farahmand |
Pharmaceutical biotechnology (Ph.D.) |
Head of Group |
| Dr. Behrad Darvishi |
Pharmacology (Ph.D) |
Faculty member |
| Aliakbar Zare |
Biotechnology(MSc) |
Faculty member |
| Malihe Salehi |
Biotechnology (MSc) |
Researcher |
| Neda Jalili |
Genetics (MSc) |
Researcher |
|
|
|
| View: 483 Time(s) | Print: 40 Time(s) | Email: 0 Time(s) | 0 Comment(s) |
|
|
| |
|
|
|
Projects |
|
|
| | Post date: 2017/11/12 | |
|
Projects:
- Cloning and Expression of recombinant scFv monoclonal antibody against hematopoietic stem cell marker CD-45Ra in bacterial host
- Design and production of a Triomab against VEGFR2 receptor, MET receptor and EpCAM molecule for targeting cancer cells in breast cancer
- Computerized simulation of Tamoxifen resistance molecular network in breast cancer cells
- Production of anti MUC1& CD3 bispecific nanobody in bacterial host
- Evaluation of Tumorocidal effects of Cardiac Peptides Expressing Salmonella on Breast cancer cell line
- Production of human recombinant scFv anti ALCAM antibody in bacterial host
- Design and fabrication of suspension microarrays based Nano biosensor for early detection of genetic diseases
- Design and production of (Fab)2 fragment antibody against anti-epidermal growth factor receptor in E.Coli
- Metastatic diagnosis of Axillary lymph nodes and tumor samples of IBCRC (Iranian Breast Cancer Research Center) based on electrical monitoring of their invasion to endothelial vascular layer cultured on nanoroughened PMMA
- Design and production of a Triomab against MUC1 receptor, CD3 receptor and Fz receptor for targeting cancer cells in breast cancer
- Design and production of anti MUC1 nanobody and Evaluation of the ER, PR, HER-2 receptors expression levels in order to overcome related drug resistance in cancer therapy
- Targeted delivery of anticancer peptide drugs to tumor site using engineered bacteria
- Efficacy and safety assessment of MUC1-CD3 Bi-Specific antibodies in breast cancer murine model
- Designing and administration of anti ERα36 antibody to overwhelm tamoxifen resistance in breast cancer cells
- Optimizing the culture medium to express a secretory form of MUC1-CD3 bi-specific antibody
- Exploring the possibility of controlling differentiation of human umbilical cord blood cells
- Evaluation of the effect of plasma-activated media on the death of MCF7 and SKBR3 cells
- Effects of extremely low frequency magnetic fields (ELF-MF) on The expression of recombinant anti-receptor CD45RA antibody fragment in bacterial host
- Exploring the effect of anti-MUC1 antibody on different cancer cells
- Design and fabrication of Nano biosensor for early detection of genetic diseases based on optical microarrays
- Efficiency of Triomab against VEGFR2 receptor, MET receptor and EpCAM molecule in breast cancer treatment via silica nanoparticles
- The effect of monoclonal MUC1 antibody loaded on pegilated carbon nanotubes on MCF7 cell line
- Nano biocompatible graphene oxide for targeted drug delivery to breast cancer cells
|
|
|
| View: 425 Time(s) | Print: 123 Time(s) | Email: 0 Time(s) | 0 Comment(s) |
|
|
| |
|
|
|
Articles |
|
|
| | Post date: 2017/11/12 | |
|
Articles:
- Mansouri S, Farahmand L, Teymourzadeh A, Majidzadeh AK. Clinical evidence on the magnitude of change in growth pathway activity in relation to Tamoxifen resistance is required. Current cancer drug targets. (Future Oncol2017).
- Mansouri S, Farahmand L, Hosseinzade A, Eslami SZ, Majidzadeh AK. Estrogen can restore Tamoxifen sensitivity in breast cancer cells amidst the complex network of resistance. (Biomedicine & Pharmacotherapy 93 (2017) 1320–1325).
- Darvishi B, Farahmand L, Eslami SZ, Majidzadeh AK. NF-kappaB as the main node of resistance to receptor tyrosine kinase inhibitors in triple-negative breast cancer. (Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2017;39(6):1010428317706919.)
- Darvishi B, Farahmand L, Majidzadeh AK. Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer.( Molecular therapy Nucleic acids. 2017;7:164-80.)
- Merikhian P, Ghadirian R, Farahmand L, Mansouri S, Majidzadeh AK. MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer.( Expert review of anticancer therapy. 2017;17(7):607-13.)
- Teymourzadeh A, Mansouri S, Farahmand L, Hosseinzade A, Majidzadeh AK. ER-alpha36 Interactions With Cytosolic Molecular Network in Acquired Tamoxifen Resistance. . (Clinical Breast Cancer (2017), doi: 10.1016/j.clbc.2017.03.013)
- Darvishi B, Farahmand L, Majidzadeh AK. Patterns of Cancer Stem Cell Negotiation with Breast Cancer Anti-angiogenic Therapy. (The Breast Journal, 2017 1–3.)
- Estiar MA, Zare AA, Esmaeili R, Farahmand L, Fazilaty H, Jafari D, et al. Clinical significance of NDRG3 in patients with breast cancer.( Future oncology. 2017;13(11):961-9.
- Mansouri S, Naghavi-Al-Hosseini F, Farahmand L, Majidzadeh AK. MED1 may explain the interaction between receptor tyrosine kinases and ERalpha66 in the complicated network of Tamoxifen resistance. (European journal of pharmacology. 2017;804:78-81.)
- Madjid Ansari A, Majidzadeh AK, Darvishi B, Sanati H, Farahmand L, Norouzian D. Extremely low frequency magnetic field enhances glucose oxidase expression in Pichia pastoris GS115.( Enzyme and microbial technology. 2017;98:67-75.)
- . Farahmand L, Darvishi B, Majidzadeh AK, Madjid Ansari A. Naturally occurring compounds acting as potent anti-metastatic agents and their suppressing effects on Hedgehog and WNT/beta-catenin signalling pathways.( Cell proliferation. 2017;50(1).)
- Farahmand L, Darvishi B, Majidzadeh-A K,. Suppression of chronic inflammation with engineered nanomaterials delivering nuclear factor κB transcription factor decoy oligodeoxynucleotides(.Drug Deliv. 2017 Nov;24(1):1249-1261.)
- Mahsa Bakhtiari, Yunes Panahi, Javad Ameli, Behrad Darvishi Protective effects of flavonoids against Alzheimer’s disease-related neural dysfunctions. (Biomedicine & Pharmacotherapy 93 (2017) 218–229).
- Fatemeh Beiraghdar, Behzad Einollahi, Alireza Ghadyani, Yunes Panahi, Abbas Hadjiakhoondib, Mahdi Vazirian, Ali Salarytabar and Behrad Darvishi, A two-week, double-blind, placebo-controlled trial of Viola odorata, Echium amoenum and Physalis alkekengi mixture in symptomatic benign prostate hyperplasia (BPH) men( .PHARMACEUTICAL BIOLOGY, .( 2017) VOL. 55, NO. 1, 1800–1805).
- Estiar MA, Esmaeili R, Zare AA, Farahmand L, Fazilaty H, Zekri A, et al. High expression of CEACAM19, a new member of carcinoembryonic antigen gene family, in patients with breast cancer.( Clinical and experimental medicine. 2016).
- Darvishi B, Farahmand L, Jalili N, Majidzadeh AK. Blinatumomab provoked fatal heart failure.( International immunopharmacology. 2016;41:42-6.)
|
|
|
| View: 505 Time(s) | Print: 160 Time(s) | Email: 0 Time(s) | 0 Comment(s) |
|
|
| |
|
|
|
.jpg)
